Geraldine Ferron‐Brady

1.2k total citations
34 papers, 577 citations indexed

About

Geraldine Ferron‐Brady is a scholar working on Hematology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Geraldine Ferron‐Brady has authored 34 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 18 papers in Molecular Biology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Geraldine Ferron‐Brady's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Geraldine Ferron‐Brady is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Monoclonal and Polyclonal Antibodies Research (13 papers). Geraldine Ferron‐Brady collaborates with scholars based in United States, United Kingdom and Australia. Geraldine Ferron‐Brady's co-authors include Tsen‐Fang Tsai, Makoto Kawashima, Ryoji Tsuboi, Kensei Katsuoka, Jennifer Gauvin, Amita Patnaik, Kyriakos P. Papadopoulos, Carlos Becerra, Gursel Aktan and Nageatte Ibrahim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Geraldine Ferron‐Brady

31 papers receiving 569 citations

Peers

Geraldine Ferron‐Brady
Antonette E. Leon Italy
Margot H. Black Canada
Cristina Bugarin Italy
A. Hamilton United States
Julie A. Di Paolo United States
Amitava Sengupta India
Simona Giglio Italy
Antonia Rodríguez Spain
Constantine Alifrangis United Kingdom
Shanta Chawla United States
Antonette E. Leon Italy
Geraldine Ferron‐Brady
Citations per year, relative to Geraldine Ferron‐Brady Geraldine Ferron‐Brady (= 1×) peers Antonette E. Leon

Countries citing papers authored by Geraldine Ferron‐Brady

Since Specialization
Citations

This map shows the geographic impact of Geraldine Ferron‐Brady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geraldine Ferron‐Brady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geraldine Ferron‐Brady more than expected).

Fields of papers citing papers by Geraldine Ferron‐Brady

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geraldine Ferron‐Brady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geraldine Ferron‐Brady. The network helps show where Geraldine Ferron‐Brady may publish in the future.

Co-authorship network of co-authors of Geraldine Ferron‐Brady

This figure shows the co-authorship network connecting the top 25 collaborators of Geraldine Ferron‐Brady. A scholar is included among the top collaborators of Geraldine Ferron‐Brady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geraldine Ferron‐Brady. Geraldine Ferron‐Brady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Musa, Hassan Hussein, Michał Mielnik, Suzanne Trudel, et al.. (2025). Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma. Haematologica. 111(2). 665–678.
3.
Polireddy, Kishore, Xialin Chen, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Pharmacokinetics. 64(6). 925–942. 2 indexed citations
4.
McCabe, Michael T., Geraldine Ferron‐Brady, Paul Martin, et al.. (2024). Momelotinib: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 17(8). e70018–e70018. 5 indexed citations
5.
Gorycki, Peter D., et al.. (2024). Clinical assessment of momelotinib drug–drug interactions via CYP3A metabolism and transporters. Clinical and Translational Science. 17(4). e13799–e13799. 3 indexed citations
6.
Ferron‐Brady, Geraldine, et al.. (2023). Building an adaptive dose simulation framework to aid dose and schedule selection. CPT Pharmacometrics & Systems Pharmacology. 12(11). 1602–1618. 2 indexed citations
7.
Rathi, Chetan, et al.. (2023). Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1411–1424. 8 indexed citations
8.
Dhar, Arindam, et al.. (2021). Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. CPT Pharmacometrics & Systems Pharmacology. 11(5). 556–568. 3 indexed citations
9.
Usmani, Saad Z., Hang Quach, Youngil Koh, et al.. (2021). DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Blood. 138(Supplement 1). 2738–2738. 15 indexed citations
10.
Cousin, Sophie, Jean‐Yves Blay, Irene García, et al.. (2020). BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. Journal of Clinical Oncology. 38(15_suppl). 3618–3618. 5 indexed citations
11.
12.
Joshi, Samit R., Disala Fernando, Thomas Greene, et al.. (2020). Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor. Pharmacology Research & Perspectives. 8(6). e00671–e00671. 22 indexed citations
13.
14.
Usmani, Saad Z., Evangelos Terpos, Wojciech Janowski, et al.. (2020). DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM).. Journal of Clinical Oncology. 38(15_suppl). TPS8556–TPS8556. 13 indexed citations
15.
Bauer, Todd M., Benjamin Besse, Alex Martínez‐Martí, et al.. (2019). Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology. 14(10). 1828–1838. 61 indexed citations
16.
Richardson, Paul G., Swethajit Biswas, Beata Holkova, et al.. (2019). Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 1857–1857. 7 indexed citations
17.
Smitheman, Kimberly N., Tesa Severson, Satyajit Rajapurkar, et al.. (2018). Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes. Haematologica. 104(6). 1156–1167. 49 indexed citations
18.
Koch, Kevin M., Geraldine Ferron‐Brady, Leanne Cartee, et al.. (2014). Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients. Clinical Pharmacology in Drug Development. 4(3). 203–209. 5 indexed citations
19.
20.
Tolcher, Anthony W., Amita Patnaik, Kyriakos P. Papadopoulos, et al.. (2014). Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology. 75(1). 183–189. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonette E. Leon Breakdown of academic impact, for papers by Margot H. Black Breakdown of academic impact, for papers by Cristina Bugarin Breakdown of academic impact, for papers by A. Hamilton Breakdown of academic impact, for papers by Julie A. Di Paolo Breakdown of academic impact, for papers by Amitava Sengupta Breakdown of academic impact, for papers by Simona Giglio Breakdown of academic impact, for papers by Antonia Rodríguez Breakdown of academic impact, for papers by Constantine Alifrangis Breakdown of academic impact, for papers by Shanta Chawla
Rankless by CCL
2026